S&P 500   3,253.94 (-1.26%)
DOW   28,620.59 (-1.27%)
QQQ   218.84 (-1.73%)
AAPL   310.48 (-2.46%)
FB   214.80 (-1.44%)
GOOGL   1,428.00 (-2.60%)
AMZN   1,837.32 (-1.31%)
NVDA   240.30 (-4.07%)
BABA   206.32 (-3.48%)
MU   55.28 (-4.29%)
GE   11.50 (-1.88%)
TSLA   554.91 (-1.75%)
AMD   49.25 (-2.20%)
T   38.45 (-0.13%)
ACB   1.96 (-1.51%)
F   8.95 (-0.56%)
NFLX   342.83 (-2.93%)
PRI   119.92 (-2.13%)
BAC   33.02 (-1.55%)
DIS   136.32 (-2.68%)
GILD   63.57 (+0.67%)
S&P 500   3,253.94 (-1.26%)
DOW   28,620.59 (-1.27%)
QQQ   218.84 (-1.73%)
AAPL   310.48 (-2.46%)
FB   214.80 (-1.44%)
GOOGL   1,428.00 (-2.60%)
AMZN   1,837.32 (-1.31%)
NVDA   240.30 (-4.07%)
BABA   206.32 (-3.48%)
MU   55.28 (-4.29%)
GE   11.50 (-1.88%)
TSLA   554.91 (-1.75%)
AMD   49.25 (-2.20%)
T   38.45 (-0.13%)
ACB   1.96 (-1.51%)
F   8.95 (-0.56%)
NFLX   342.83 (-2.93%)
PRI   119.92 (-2.13%)
BAC   33.02 (-1.55%)
DIS   136.32 (-2.68%)
GILD   63.57 (+0.67%)
S&P 500   3,253.94 (-1.26%)
DOW   28,620.59 (-1.27%)
QQQ   218.84 (-1.73%)
AAPL   310.48 (-2.46%)
FB   214.80 (-1.44%)
GOOGL   1,428.00 (-2.60%)
AMZN   1,837.32 (-1.31%)
NVDA   240.30 (-4.07%)
BABA   206.32 (-3.48%)
MU   55.28 (-4.29%)
GE   11.50 (-1.88%)
TSLA   554.91 (-1.75%)
AMD   49.25 (-2.20%)
T   38.45 (-0.13%)
ACB   1.96 (-1.51%)
F   8.95 (-0.56%)
NFLX   342.83 (-2.93%)
PRI   119.92 (-2.13%)
BAC   33.02 (-1.55%)
DIS   136.32 (-2.68%)
GILD   63.57 (+0.67%)
S&P 500   3,253.94 (-1.26%)
DOW   28,620.59 (-1.27%)
QQQ   218.84 (-1.73%)
AAPL   310.48 (-2.46%)
FB   214.80 (-1.44%)
GOOGL   1,428.00 (-2.60%)
AMZN   1,837.32 (-1.31%)
NVDA   240.30 (-4.07%)
BABA   206.32 (-3.48%)
MU   55.28 (-4.29%)
GE   11.50 (-1.88%)
TSLA   554.91 (-1.75%)
AMD   49.25 (-2.20%)
T   38.45 (-0.13%)
ACB   1.96 (-1.51%)
F   8.95 (-0.56%)
NFLX   342.83 (-2.93%)
PRI   119.92 (-2.13%)
BAC   33.02 (-1.55%)
DIS   136.32 (-2.68%)
GILD   63.57 (+0.67%)
Log in

NASDAQ:AVRO - Avrobio Stock Price, Forecast & News

$19.45
-0.15 (-0.77 %)
(As of 01/27/2020 12:14 PM ET)
Today's Range
$18.49
Now: $19.45
$19.57
50-Day Range
$17.96
MA: $20.37
$22.78
52-Week Range
$11.85
Now: $19.45
$28.52
Volume24,405 shs
Average Volume130,595 shs
Market Capitalization$615.98 million
P/E RatioN/A
Dividend YieldN/A
Beta2.76
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVRO
CUSIPN/A
CIKN/A
Phone617-914-8420

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.10 per share

Profitability

Net Income$-46,360,000.00

Miscellaneous

Employees49
Market Cap$615.98 million
Next Earnings Date3/23/2020 (Estimated)
OptionableNot Optionable

Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.


Avrobio (NASDAQ:AVRO) Frequently Asked Questions

What is Avrobio's stock symbol?

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

How were Avrobio's earnings last quarter?

Avrobio Inc (NASDAQ:AVRO) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.57) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.59) by $0.02. View Avrobio's Earnings History.

When is Avrobio's next earnings date?

Avrobio is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Avrobio.

What price target have analysts set for AVRO?

6 brokerages have issued twelve-month price objectives for Avrobio's stock. Their forecasts range from $24.42 to $43.00. On average, they anticipate Avrobio's stock price to reach $33.08 in the next year. This suggests a possible upside of 70.1% from the stock's current price. View Analyst Price Targets for Avrobio.

What is the consensus analysts' recommendation for Avrobio?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avrobio.

Has Avrobio been receiving favorable news coverage?

News articles about AVRO stock have trended somewhat negative this week, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Avrobio earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Avrobio.

Are investors shorting Avrobio?

Avrobio saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 1,610,000 shares, a decline of 8.5% from the December 31st total of 1,760,000 shares. Based on an average daily trading volume, of 180,400 shares, the days-to-cover ratio is presently 8.9 days. Currently, 7.2% of the shares of the company are short sold. View Avrobio's Current Options Chain.

Who are some of Avrobio's key competitors?

What other stocks do shareholders of Avrobio own?

Who are Avrobio's key executives?

Avrobio's management team includes the folowing people:
  • Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 53)
  • Mr. Steven N. Avruch, VP, Gen. Counsel & Sec. (Age 58)
  • Mr. Jeffrey Medin Ph.D., Scientific Founder
  • Mr. Erik Ostrowski, CFO & Treasurer (Age 46)
  • Dr. Kim Warren, Head of Operations

When did Avrobio IPO?

(AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

Who are Avrobio's major shareholders?

Avrobio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.08%) and Patriot Financial Group Insurance Agency LLC (0.01%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay. View Institutional Ownership Trends for Avrobio.

Which institutional investors are buying Avrobio stock?

AVRO stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC and Patriot Financial Group Insurance Agency LLC. View Insider Buying and Selling for Avrobio.

How do I buy shares of Avrobio?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Avrobio's stock price today?

One share of AVRO stock can currently be purchased for approximately $19.45.

How big of a company is Avrobio?

Avrobio has a market capitalization of $615.98 million. The company earns $-46,360,000.00 in net income (profit) each year or ($3.62) on an earnings per share basis. Avrobio employs 49 workers across the globe.View Additional Information About Avrobio.

What is Avrobio's official website?

The official website for Avrobio is http://www.avrobio.com/.

How can I contact Avrobio?

Avrobio's mailing address is ONE KENDALL SQUARE BLDG. 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]


MarketBeat Community Rating for Avrobio (NASDAQ AVRO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  214
MarketBeat's community ratings are surveys of what our community members think about Avrobio and other stocks. Vote "Outperform" if you believe AVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel